A phase II trial of piroxantrone in adenocarcinoma of the pancreas
- 18 Downloads
Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0% –10%). Toxicities of grade ≥ 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.
Key wordspiroxantrone adenocarcinoma of the pancreas
Unable to display preview. Download preview PDF.
- 2.Brennan MF, Kinsella TJ, Friedman M: Cancer of the Pancreas.In DeVita VT, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, pp. 800–835. Philadelphia, JB Lippincott, third edition, 1989Google Scholar
- 5.Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amsacrine analogues in mouse and human leukemiain vitro andin vivo. Proc Am Assoc Cancer Res 26:339, 1985Google Scholar